Arrowhead Closes Licensing, Collaboration Agreement With Sarepta

MT Newswires Live

Feb 10, 2025

Arrowhead Pharmaceuticals (ARWR) said Monday it has closed its licensing and collaboration agreement with Sarepta Therapeutics (SRPT), with Arrowhead getting a $500 million upfront payment and $325 million for the purchase by Sarepta of Arrowhead stock at $27.25 per share.

Arrowhead also said it will get $250 million to be paid in annual installments of $50 million over five years and may also get $300 million in near-term payments related to the enrollment of some groups of a phase 1/2 trial of ARO-DM1.

Additionally, Arrowhead said it may get development milestone payments of between $110 million and $410 million per program and sales milestone payments of between $500 million and $700 million per program as well as royalties on sales up to the low double digits.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510986360"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510986360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510986360?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510986360","market":"us","top_or_hot":-1,"title":"Arrowhead Closes Licensing, Collaboration Agreement With Sarepta","media":"MT Newswires Live","content":"<html><body><p> Arrowhead Pharmaceuticals (ARWR) said Monday it has closed its licensing and collaboration agreement with <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> (SRPT), with Arrowhead getting a $500 million upfront payment and $325 million for the purchase by Sarepta of Arrowhead stock at $27.25 per share.</p><p>Arrowhead also said it will get $250 million to be paid in annual installments of $50 million over five years and may also get $300 million in near-term payments related to the enrollment of some groups of a phase 1/2 trial of ARO-DM1.</p><p>Additionally, Arrowhead said it may get development milestone payments of between $110 million and $410 million per program and sales milestone payments of between $500 million and $700 million per program as well as royalties on sales up to the low double digits.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrowhead Closes Licensing, Collaboration Agreement With Sarepta</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrowhead Closes Licensing, Collaboration Agreement With Sarepta\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-10 22:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Arrowhead Pharmaceuticals (ARWR) said Monday it has closed its licensing and collaboration agreement with <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> (SRPT), with Arrowhead getting a $500 million upfront payment and $325 million for the purchase by Sarepta of Arrowhead stock at $27.25 per share.</p><p>Arrowhead also said it will get $250 million to be paid in annual installments of $50 million over five years and may also get $300 million in near-term payments related to the enrollment of some groups of a phase 1/2 trial of ARO-DM1.</p><p>Additionally, Arrowhead said it may get development milestone payments of between $110 million and $410 million per program and sales milestone payments of between $500 million and $700 million per program as well as royalties on sales up to the low double digits.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B2B36J28.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510986360","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510986360","pubTimestamp":1739198254,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arrowhead Pharmaceuticals  said Monday it has closed its licensing and collaboration agreement with Sarepta Therapeutics , with Arrowhead getting a $500 million upfront payment and $325 million for the purchase by Sarepta of Arrowhead stock at $27.25 per share.Arrowhead also said it will get $250 million to be paid in annual installments of $50 million over five years and may also get $300 million in near-term payments related to the enrollment of some groups of a phase 1/2 trial of ARO-DM1.Additionally, Arrowhead said it may get development milestone payments of between $110 million and $410 million per program and sales milestone payments of between $500 million and $700 million per program as well as royalties on sales up to the low double digits.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","BK4588":"碎股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4139":"生物科技","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SRPT":"Sarepta Therapeutics","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","ARWR":"Arrowhead Research Corporation"},"translate_title":"Arrowhead与Sarepta签订许可和合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":0.9,"ARWR":0.9},"content_text":"Arrowhead Pharmaceuticals (ARWR) said Monday it has closed its licensing and collaboration agreement with Sarepta Therapeutics (SRPT), with Arrowhead getting a $500 million upfront payment and $325 million for the purchase by Sarepta of Arrowhead stock at $27.25 per share.Arrowhead also said it will get $250 million to be paid in annual installments of $50 million over five years and may also get $300 million in near-term payments related to the enrollment of some groups of a phase 1/2 trial of ARO-DM1.Additionally, Arrowhead said it may get development milestone payments of between $110 million and $410 million per program and sales milestone payments of between $500 million and $700 million per program as well as royalties on sales up to the low double digits.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}